COMPOSITION:
Each film-coated tablet contains
Linagliptin…………………. 5 mg
Dapagliflozin……………… 10 mg
Metformin SR…………….. 500 mg
DESCRIPTION:
Linagliptin:
Linagliptin is a potent, reversible, and selective inhibitor of the enzyme DPP-4 (Dipeptidyl peptidase-4) which is involved in the inactivation of the incretin hormones- glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). These incretin hormones are rapidly degraded by the enzyme DPP-4. GLP-1 and GIP increase insulin biosynthesis and secretion from pancreatic beta cells in the presence of normal and elevated blood glucose levels. Furthermore, GLP-1 also reduces glucagon secretion from pancreatic alpha cells, resulting in a reduction in hepatic glucose production. Linagliptin binds to DPP-4 enzyme in a reversible manner and thus leads to an increase and a prolongation of active incretin levels. Linagliptin glucose-dependently increases insulin secretion and lowers glucagon secretion thus resulting in an overall improvement in glucose homeostasis.
Dapagliflozin:
Sodium-glucose cotransporter-2 (SGLT2), expressed in the proximal renal tubules, is responsible for the majority of the reabsorption of filtered glucose from the tubular lumen. Dapagliflozin is an inhibitor of SGLT2. By inhibiting SGLT2, dapagliflozin reduces the reabsorption of filtered glucose and lowers the renal threshold for glucose, and thereby increasing urinary glucose excretion.
Metformin:
Metformin is an antihyperglycemic agent that improves glucose tolerance in patients with type 2 diabetes, lowering both basal and postprandial plasma glucose. Metformin decreases hepatic glucose production, decreases intestinal absorption of glucose, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization. Unlike sulfonylureas, metformin does not produce significant hypoglycemia in either patients with type 2 diabetes or normal subjects and does not cause hyperinsulinemia
INDICATIONS & USAGE:
Linapaz DM is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treated.
DOSAGE & ADMINISTRATION:
As directed by the physician.
CONTRA-INDICATIONS:
– Moderate to severe renal impairment.
– History of serious hypersensitivity to linagliptin, dapagliflozin, or metformin.
DISCLAIMER:
All content published online is for informational purposes only. It is not intended to be a substitute for professional medical advice. Always seek the guidance of your doctor with any questions you may have regarding your health, medical condition, or any medicines.